Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of CC-11050 and Metformin for Patients with Rifampin-Resistant Tuberculosis

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for rifampin-resistant pulmonary tuberculosis, a type of lung infection that does not respond to the usual antibiotic, rifampin. The study will test two additional treatments alongside standard care. One treatment is an anti-inflammatory drug with the code name CC-11050, which is designed to reduce inflammation in the body. The other treatment is Metformin, a medication commonly used to treat diabetes, which may have additional benefits in fighting infections.

The purpose of the study is to explore the safety and initial effectiveness of these two treatments in helping patients recover lung function and clear the infection. Participants will be randomly assigned to receive either the new treatments or a placebo, in addition to their regular tuberculosis medication. The study will last for up to 24 months, with regular check-ups to monitor health and progress.

Throughout the study, doctors will assess how well the treatments work by looking at lung function and the ability to clear the tuberculosis infection. The goal is to find out if these additional treatments can help improve outcomes for patients with this challenging form of tuberculosis. The study will compare the results of those taking CC-11050 and Metformin to those who do not receive these additional treatments.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history, a physical examination, and laboratory tests to ensure the presence of rifampin-resistant pulmonary tuberculosis.

    Eligibility criteria include being between 16 and 65 years old, having a body weight between 30 and 90 kg, and a positive sputum test for tuberculosis with rifampin resistance.

  2. Step 2

    Treatment allocation

    Participants are randomly assigned to one of the treatment groups. The study investigates two therapies: an anti-inflammatory and an antimicrobial treatment.

    The medications used include Metformin Zentiva 500 mg film-coated tablets, taken orally. The specific dosage and frequency are determined by the study protocol.

  3. Step 3

    Treatment phase

    During the treatment phase, participants take the assigned medication as directed. The treatment aims to improve lung function and eradicate the tuberculosis infection.

    Regular follow-up visits are scheduled to monitor safety, tolerability, and the effectiveness of the treatment. These visits include physical examinations and laboratory tests.

  4. Step 4

    Evaluation of primary endpoints

    At month 6, the primary endpoints are evaluated. These include the recovery of lung function and the eradication of the tuberculosis infection.

    The success of the treatment is determined by meeting both co-primary endpoints: improvement in lung function and stable culture conversion.

  5. Step 5

    Long-term follow-up

    Participants continue to be monitored for up to 18 months after entering the study. This long-term follow-up assesses the durability of the treatment effects and any potential long-term side effects.

    The study is expected to conclude by December 31, 2025.

Who can join the trial?

8 criteria

  • Must be between the ages of 16 and 65.
  • Must be able and willing to provide signed written consent. If unable to write, verbal consent from witnesses is acceptable. For those aged 16 or 17, consent from a parent or guardian is also required.
  • Body weight should be between 30 and 90 kg (measured in light clothing without shoes).
  • Must have a positive sputum test for tuberculosis (TB) using a test called Xpert, with a specific result called Ct ≤22, and this must be confirmed by a culture test.
  • Must have resistance to a TB medication called **Rifampicin**, confirmed by specific tests (Xpert, Hain test, or phenotypic drug susceptibility testing).
  • Must have a chest X-ray that meets criteria for moderate or very advanced **pulmonary tuberculosis** as defined by the National TB Association.
  • If sexually active, must be willing to use an effective method of birth control during TB treatment.
  • Must be **HIV-1 seronegative** (not infected with HIV-1), or if **HIV-1 seropositive** (infected with HIV-1), must be at an African study site with a **CD4 T-cell count** greater than 100/μl and either currently receiving **ART** (antiretroviral therapy) or willing to start ART during the study. Note: HIV+ patients will only be enrolled in African sites.

Who cannot join the trial?

4 criteria

  • Patients who do not have multidrug-resistant pulmonary tuberculosis cannot participate. This means the tuberculosis in their lungs does not resist multiple drugs used for treatment.
  • Patients who are not resistant to Rifampicin cannot participate. Rifampicin is a common antibiotic used to treat tuberculosis.
  • Patients who are not within the specified age range cannot participate. The study includes certain age groups only.
  • Patients who are part of a vulnerable population cannot participate. Vulnerable populations may include groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • CC11050

    is an anti-inflammatory medication being tested to see if it can help reduce inflammation in patients with rifampin-resistant tuberculosis. The goal is to see if it can improve lung function and help clear the infection more effectively when used alongside standard tuberculosis treatments.

  • Metformin

    is an antimicrobial medication commonly used to treat diabetes, but in this trial, it is being tested for its potential to help fight tuberculosis infection. Researchers are investigating whether it can enhance the effectiveness of tuberculosis treatment and improve recovery of lung function in patients with rifampin-resistant tuberculosis.

What is already known about the treatment

  • CC11050

    This medication is administered orally and is currently being studied in clinical trials for its potential use in treating multidrug-resistant pulmonary tuberculosis. It is an anti-inflammatory agent that aims to enhance the body's immune response to fight the infection. The drug works by modulating specific pathways in the immune system to reduce inflammation and improve lung function. It is classified as an immunomodulatory agent and is being evaluated for its safety and effectiveness in combination with other treatments.

  • Metformin

    This medication is also taken orally and is well-known for its use in managing type 2 diabetes. In the context of the clinical trial, it is being investigated for its potential antimicrobial properties against multidrug-resistant pulmonary tuberculosis. Metformin is thought to work by affecting cellular metabolism and enhancing the immune response to help clear the infection. It belongs to the class of biguanides and is being assessed for its ability to improve treatment outcomes when used alongside standard tuberculosis therapies.

Investigated diseases

Multidrug-Resistant Pulmonary Tuberculosis – This is a form of tuberculosis that affects the lungs and is resistant to at least two of the most powerful anti-TB drugs, including rifampicin. The disease is caused by the bacterium Mycobacterium tuberculosis, which primarily attacks the lungs but can also affect other parts of the body. It spreads through the air when an infected person coughs or sneezes. The progression of the disease can lead to severe lung damage, causing symptoms such as a persistent cough, chest pain, and difficulty breathing. Over time, if untreated, it can result in significant respiratory issues and reduced lung function. The disease requires specialized treatment due to its resistance to standard medications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2025-520745-80-00Protocol codeAUR1-1-313 DRTB-HDTEstimated enrolment330 patientsSponsorQuality Regulatory Clinical Ireland Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).